文献速递疼痛医学术前评估与围术期医学

腰椎小关节射频消融后阿片类药物处方与新发持续使用相关

Opioid Fills for Lumbar Facet Radiofrequency Ablation Associated with New Persistent Opioid Use.
PubMed 文献 · Anesthesiology · 2020-01-01

这项回顾性队列研究利用美国保险理赔数据库,纳入2887例既往未使用阿片类药物的腰椎射频消融患者,发现围术期阿片类药物处方填充与新发持续阿片使用独立相关(aOR 2.35,95%CI 1.51-3.66,P<0.001),提示应重新评估此类手术后的阿片处方。

要点

  • 围术期阿片处方填充者新发持续使用率为5.6%,未填充者为2.8%。
  • 围术期阿片处方填充与新发持续使用独立相关(aOR 2.35)。
  • 腰椎射频消融后应重新评估并可能停用阿片处方。

核心结论

  • 腰椎射频消融围术期阿片使用与既往未使用阿片患者的新发持续使用独立相关。
  • 新暴露于阿片是慢性背痛射频消融患者持续使用的独立危险因素。
  • 应重新评估并可能停用射频消融后的阿片处方。

研究设计与样本

  • 回顾性队列研究,使用Clinformatics Data Mart数据库理赔数据。
  • 纳入18至64岁既往未使用阿片且接受腰椎射频消融的患者。
  • 排除主要操作后15至180天再次射频消融或180天内手术的患者。
  • 共2887例患者符合纳入标准。

主要发现

  • 2277例(78.9%)围术期无阿片处方填充,610例(21.1%)有填充。
  • 有填充组新发持续阿片使用未调整率为5.6%(34例),无填充组为2.8%(63例)。
  • 围术期阿片处方填充与新发持续使用独立相关(调整OR 2.35;95%CI 1.51至3.66;P<0.001)。

关键数值与推荐

  • 新发持续阿片使用定义为射频消融后8至90天及91至180天期间均有阿片处方 fulfillment。
  • 围术期阿片处方填充与新发持续使用的调整OR为2.35(95%CI 1.51至3.66;P<0.001)。

临床怎么用

  • 对既往未使用阿片的腰椎射频消融患者,围术期应审慎开具阿片处方。
  • 术后应重新评估阿片处方的必要性,并考虑停用。

局限性

  • 回顾性设计可能受未测量混杂因素影响。
  • 基于理赔数据,可能存在处方填充与真实用药差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Zygapophyseal (facet) joint interventions are the second most common interventional procedure in pain medicine. Opioid exposure after surgery is a significant risk factor for chronic opioid use. The aim of this study was to determine the incidence of new persistent use of opioids after lumbar facet radiofrequency ablation and to assess the effect of postprocedural opioid prescribing on the development of new persistent opioid use. METHODS: The authors conducted a retrospective cohort study using claims from the Clinformatics Data Mart Database (OptumInsight, USA) to identify opioid-naïve patients between 18 and 64 yr old who had lumbar radiofrequency ablation. Patients who had either subsequent radiofrequency ablation 15 to 180 days or subsequent surgery within 180 days after the primary procedure were excluded from the analysis. The primary outcome was new persistent opioid use, defined as opioid prescription fulfillment within the 8 to 90 and 91 to 180 day periods after radiofrequency ablation. The authors then assessed patient-level risk factors for new persistent opioid use. RESULTS: A total of 2,887 patients met the inclusion criteria. Of those patients, 2,277 (78.9%) had radiofrequency ablation without a perioperative opioid fill, and 610 (21.1%) patients had the procedure with a perioperative opioid fill. The unadjusted rate of new persistent opioid use was 5.6% (34 patients) in the group with a perioperative opioid fill versus 2.8% (63 patients) for those without an opioid fill. Periprocedural opioid prescription fill was independently associated with increased odds of new persistent use (adjusted odds ratio, 2.35; 95% CI, 1.51 to 3.66; P < 0.001). CONCLUSIONS: Periprocedural opioid use after lumbar radiofrequency ablation was associated with new persistent use in previously opioid-naïve patients, suggesting that new exposure to opioids is an independent risk factor for persistent use in patients having radiofrequency ablation for chronic back pain. Opioid prescribing after radiofrequency ablation should be reevaluated and likely discontinued in this population.

来源:Anesthesiology,查看原文。版权归原作者所有。

引用

  1. Southren DL, Moser S, Abu-Amara H, et al. Opioid Fills for Lumbar Facet Radiofrequency Ablation Associated with New Persistent Opioid Use. Anesthesiology. 2020. PMID: 32011343. doi:10.1097/ALN.0000000000003164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。